Meeting
2012 Genitourinary Cancers Symposium
Association of GSTP1, COMT, and TPMT with testicular cancer (TC) treatment outcome after cisplatin-based chemotherapy (CBCT).
Authors
Chunkit Fung
University of Rochester Medical Center, Rochester, NY
Chunkit Fung , David J. Vaughn , Nandita Mitra , Stephanie L. Ciosek , Saran Vardhanabhuti , Katherine L. Nathanson , Peter A. Kanetsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session D: Penile, Urethral, Urothelial, and Testicular Cancers
Track
Urothelial Carcinoma,Penile, Urethral, and Testicular Cancer
Sub Track
Penile, Urethral, and Testicular Cancer
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 344)
DOI
10.1200/jco.2012.30.5_suppl.344
Abstract #
344
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Comprehensive characterization of cisplatin-related hearing loss in U.S. and Canadian Testicular Cancer Survivors (TCS).
First Author: Heather E. Wheeler
Poster
2021 Genitourinary Cancers Symposium
Paternity, relationship, sexual activity and fertility in testicular cancer (TC) survivors (TCS): Results from a single institution observational prospective study.
First Author: Davide Bimbatti
Poster
2018 ASCO Annual Meeting
Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).
First Author: Deaglan Joseph McHugh
Poster
2018 Genitourinary Cancers Symposium
Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).
First Author: Deaglan Joseph McHugh